Enveric Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 1.43 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.40M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary...